AUTHOR=Wei Chao-Gang , Zhang Rui , Wei Lan-Yi , Pan Peng , Zu He , Liu Ya-Zhen , Wang Yong , Shen Jun-Kang 

TITLE=Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy

JOURNAL=Frontiers in Bioengineering and Biotechnology

VOLUME=Volume 10 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2022.1078342

DOI=10.3389/fbioe.2022.1078342

ISSN=2296-4185

ABSTRACT=Erythropoietin producing hepatocyte receptor A2 (EphA2) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation. Based on its high expression in castration-resistant prostate cancer (CRPC), we herein develop a CRISPR-Cas9-based genome-editing nanomedicine to target EphA2 for the treatment of CRPC. To this end, TAT was designed to stabilize the distribution of calcium, and then bound to ribonucleoprotein (RNP) to form nanoparticles RNP@CaP-TAT. This nanoparticle has a simple synthesis process with good biocompatible, to achieve the knockout of tumor cells (PC-3) targeting EphA2 gene and to effectively suppress the migration of tumor cells. This delivery genome editing system provides a promising gene therapy strategy for the treatment of CRPC, showing good potential against CRPC tumor metastasis. In addition, it can be extended to other types of cancer with highly heterogeneous gene expression.